{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T16:01:26Z","timestamp":1795017686895,"version":"4.10.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T00:00:00Z","timestamp":1687564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T00:00:00Z","timestamp":1687564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Unitaid under the BOHEMIA grant"},{"DOI":"10.13039\/501100004837","name":"Spanish Ministry of Science and Innovation","doi-asserted-by":"crossref","award":["Centro de Excelencia Severo Ochoa 2019-2023"],"award-info":[{"award-number":["Centro de Excelencia Severo Ochoa 2019-2023"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"crossref","award":["CERCA program"],"award-info":[{"award-number":["CERCA program"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008375","name":"University of Basel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Ivermectin (22,23-dihydroavermectin B\n                      <jats:sub>1a<\/jats:sub>\n                      : H\n                      <jats:sub>2<\/jats:sub>\n                      B\n                      <jats:sub>1a<\/jats:sub>\n                      ) is an endectocide used to treat worm infections and ectoparasites including lice and scabies mites. Furthermore, survival of malaria transmitting\n                      <jats:italic>Anopheles<\/jats:italic>\n                      mosquitoes is strongly decreased after feeding on humans recently treated with ivermectin. Currently, mass drug administration of ivermectin is under investigation as a potential novel malaria vector control tool to reduce\n                      <jats:italic>Plasmodium<\/jats:italic>\n                      transmission by mosquitoes. A \u201cpost-ivermectin effect\u201d has also been reported, in which the survival of mosquitoes remains reduced even after ivermectin is no longer detectable in blood meals. In the present study, existing material from human clinical trials was analysed to understand the pharmacokinetics of ivermectin metabolites and feeding experiments were performed in\n                      <jats:italic>Anopheles stephensi<\/jats:italic>\n                      mosquitoes to assess whether ivermectin metabolites contribute to the mosquitocidal action of ivermectin and whether they may be responsible for the post-ivermectin effect.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Ivermectin was incubated in the presence of recombinant human cytochrome P\n                      <jats:sub>450<\/jats:sub>\n                      3A4\/5 (CYP 3A4\/5) to produce ivermectin metabolites. In total, nine metabolites were purified by semi-preparative high-pressure liquid chromatography. The pharmacokinetics of the metabolites were assessed over three days in twelve healthy volunteers who received a single oral dose of 12\u00a0mg ivermectin. Blank whole blood was spiked with the isolated metabolites at levels matching the maximal blood concentration (C\n                      <jats:sub>max<\/jats:sub>\n                      ) observed in pharmacokinetics study samples. These samples were fed to\n                      <jats:italic>An. stephensi<\/jats:italic>\n                      mosquitoes, and their survival and vitality was recorded daily over 3 days.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Human CYP3A4 metabolised ivermectin more rapidly than CYP3A5. Ivermectin metabolites M1\u2013M8 were predominantly formed by CYP3A4, whereas metabolite M9 (hydroxy-H\n                      <jats:sub>2<\/jats:sub>\n                      B\n                      <jats:sub>1a<\/jats:sub>\n                      ) was mainly produced by CYP3A5. Both desmethyl-H\n                      <jats:sub>2<\/jats:sub>\n                      B\n                      <jats:sub>1a<\/jats:sub>\n                      (M1) and hydroxy-H\n                      <jats:sub>2<\/jats:sub>\n                      B\n                      <jats:sub>1a<\/jats:sub>\n                      (M2) killed all mosquitoes within three days post-feeding, while administration of desmethyl, hydroxy-H\n                      <jats:sub>2<\/jats:sub>\n                      B\n                      <jats:sub>1a<\/jats:sub>\n                      (M4) reduced survival to 35% over an observation period of 3 days. Ivermectin metabolites that underwent deglycosylation or hydroxylation at spiroketal moiety were not active against\n                      <jats:italic>An. stephensi<\/jats:italic>\n                      at C\n                      <jats:sub>max<\/jats:sub>\n                      levels. Interestingly, half-lives of M1 (54.2\u2009\u00b1\u20094.7\u00a0h) and M4 (57.5\u2009\u00b1\u200913.2\u00a0h) were considerably longer than that of the parent compound ivermectin (38.9\u2009\u00b1\u200920.8\u00a0h).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In conclusion, the ivermectin metabolites M1 and M2 contribute to the activity of ivermectin against\n                      <jats:italic>An. stephensi<\/jats:italic>\n                      mosquitoes and could be responsible for the \u201cpost-ivermectin effect\u201d.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-023-04624-0","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T03:01:42Z","timestamp":1687575702000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Pharmacokinetics of ivermectin metabolites and their activity against Anopheles stephensi mosquitoes"],"prefix":"10.1186","volume":"22","author":[{"given":"Charlotte","family":"Kern","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pie","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Chaccour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias E.","family":"Liechti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Hammann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urs","family":"Duthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,24]]},"reference":[{"key":"4624_CR1","unstructured":"WHO. World malaria report 2021. Geneva, World Health Organization, 2021. https:\/\/www.who.int\/publications-detail-redirect\/9789240040496. Accessed 8 Dec 2021."},{"key":"4624_CR2","unstructured":"WHO. Tailoring malaria interventions in the COVID-19 response. Geneva, World Health Organization, 2020. http:\/\/www.who.int\/malaria\/publications\/atoz\/tailoring-malaria-interventions-in-the-covid-19-response\/en\/. Accessed 14 May 2020."},{"key":"4624_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4269\/ajtmh.19-0620","volume":"102","author":"The Ivermectin Roadmappers","year":"2020","unstructured":"The Ivermectin Roadmappers. A roadmap for the development of ivermectin as a complementary malaria vector control tool. Am J Trop Med Hyg. 2020;102:3\u201324.","journal-title":"Am J Trop Med Hyg"},{"key":"4624_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s12936-017-1801-4","volume":"16","author":"C Chaccour","year":"2017","unstructured":"Chaccour C, Hammann F, Rabinovich NR. Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety. Malar J. 2017;16:161.","journal-title":"Malar J"},{"key":"4624_CR5","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/j.1365-3156.2008.02049.x","volume":"13","author":"B Thylefors","year":"2008","unstructured":"Thylefors B, Alleman MM, Twum-Danso NAY. Operational lessons from 20 years of the Mectizan Donation Program for the control of onchocerciasis. Trop Med Int Health. 2008;13:689\u201396.","journal-title":"Trop Med Int Health"},{"key":"4624_CR6","unstructured":"Mectizan Donation Program. Annual Highlights [Internet]. Mectizan Donation Program. 2022. https:\/\/mectizan.org\/news_resources\/2021-mectizan-donation-program-annual-highlights\/. Accessed 15 Jun 2022."},{"key":"4624_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003507","volume":"9","author":"J Lawrence","year":"2015","unstructured":"Lawrence J, Sodahlon YK, Ogoussan KT, Hopkins AD. Growth, challenges, and solutions over 25 years of Mectizan and the impact on Onchocerciasis control. PLoS Negl Trop Dis. 2015;9: e0003507.","journal-title":"PLoS Negl Trop Dis"},{"issue":"Suppl 1","key":"4624_CR8","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1186\/1475-2883-2-S1-S7","volume":"2","author":"NA Twum-Danso","year":"2003","unstructured":"Twum-Danso NA. Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future. Filar J. 2003;2(Suppl 1):S7.","journal-title":"Filar J"},{"key":"4624_CR9","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1242\/jeb.118570","volume":"218","author":"JI Meyers","year":"2015","unstructured":"Meyers JI, Gray M, Kuklinski W, Johnson LB, Snow CD, Black WC, et al. Characterization of the target of ivermectin, the glutamate-gated chloride channel, from Anopheles gambiae. J Exp Biol. 2015;218:1478\u201386.","journal-title":"J Exp Biol"},{"key":"4624_CR10","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/0035-9203(85)90121-X","volume":"79","author":"S Pampiglione","year":"1985","unstructured":"Pampiglione S, Majori G, Petrangeli G, Romi R. Avermectins, MK-933 and MK-936, for mosquito control. Trans R Soc Trop Med Hyg. 1985;79:797\u20139.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"4624_CR11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S1473-3099(18)30163-4","volume":"18","author":"MR Smit","year":"2018","unstructured":"Smit MR, Ochomo EO, Aljayyoussi G, Kwambai TK, Abong\u2019o BO, Chen T, et al. Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2018;18:615\u201326.","journal-title":"Lancet Infect Dis"},{"key":"4624_CR12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12936-018-2296-3","volume":"17","author":"SM Dreyer","year":"2018","unstructured":"Dreyer SM, Morin KJ, Vaughan JA. Differential susceptibilities of Anopheles albimanus and Anopheles stephensi mosquitoes to ivermectin. Malar J. 2018;17:148.","journal-title":"Malar J"},{"key":"4624_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12936-017-1885-x","volume":"16","author":"IN Lyimo","year":"2017","unstructured":"Lyimo IN, Kessy ST, Mbina KF, Daraja AA, Mnyone LL. Ivermectin-treated cattle reduces blood digestion, egg production and survival of a free-living population of Anopheles arabiensis under semi-field condition in south-eastern Tanzania. Malar J. 2017;16:239.","journal-title":"Malar J"},{"key":"4624_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.actatropica.2011.10.007","volume":"121","author":"MP Butters","year":"2012","unstructured":"Butters MP, Kobylinski KC, Deus KM, da Silva IM, Gray M, Sylla M, et al. Comparative evaluation of systemic drugs for their effects against Anopheles gambiae. Acta Trop. 2012;121:34\u201343.","journal-title":"Acta Trop"},{"key":"4624_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1086\/653208","volume":"202","author":"C Chaccour","year":"2010","unstructured":"Chaccour C, Lines J, Whitty CJM. Effect of ivermectin on Anopheles gambiae mosquitoes fed on humans: the potential of oral insecticides in malaria control. J Infect Dis. 2010;202:113\u20136.","journal-title":"J Infect Dis"},{"key":"4624_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009382","volume":"17","author":"U Duthaler","year":"2021","unstructured":"Duthaler U, Weber M, Hofer L, Chaccour C, Maia M, M\u00fcller P, et al. The pharmacokinetics and drug-drug interactions of ivermectin in Aedes aegypti mosquitoes. PLOS Pathog. 2021;17: e1009382.","journal-title":"PLOS Pathog"},{"key":"4624_CR17","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1603\/ME11164","volume":"49","author":"KM Deus","year":"2012","unstructured":"Deus KM, Saavedra-rodriguez K, Butters MP, Black WC, Foy BD. The effect of ivermectin in seven strains of Aedes aegypti (Diptera: Culicidae) including a genetically diverse laboratory strain and three permethrin resistant strains. J Med Entomol. 2012;49:356\u201363.","journal-title":"J Med Entomol"},{"key":"4624_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.actatropica.2010.06.001","volume":"116","author":"KC Kobylinski","year":"2010","unstructured":"Kobylinski KC, Deus K, Butters M, Hongyu T, Gray M, da Silva I, et al. The effect of oral anthelmintics on the survivorship and re-feeding frequency of anthropophilic mosquito disease vectors. Acta Trop. 2010;116:119\u201326.","journal-title":"Acta Trop"},{"key":"4624_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13071-020-04512-5","volume":"14","author":"M Hadlett","year":"2021","unstructured":"Hadlett M, Nagi SC, Sarkar M, Paine MJI, Weetman D. High concentrations of membrane-fed ivermectin are required for substantial lethal and sublethal impacts on Aedes aegypti. Parasit Vectors. 2021;14:9.","journal-title":"Parasit Vectors"},{"key":"4624_CR20","first-page":"79","volume":"42","author":"MH Elkassaby","year":"1991","unstructured":"Elkassaby MH. Ivermectin uptake and distribution in the plasma and tissue of Sudanese and Mexican patients infected with Onchocerca volvulus. Trop Med Parasitol. 1991;42:79\u201381.","journal-title":"Trop Med Parasitol"},{"key":"4624_CR21","unstructured":"FDA. Drug Approval Package: Stromectol (Ivermectin) NDA# 050742s001. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/98\/50-742s001_Stromectol.cfm. Accessed 12 Apr 2023."},{"key":"4624_CR22","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/1475-2875-9-365","volume":"9","author":"M Sylla","year":"2010","unstructured":"Sylla M, Kobylinski KC, Gray M, Chapman PL, Sarr MD, Rasgon JL, et al. Mass drug administration of ivermectin in south-eastern Senegal reduces the survivorship of wild-caught, blood fed malaria vectors. Malar J. 2010;9:365.","journal-title":"Malar J"},{"key":"4624_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4269\/ajtmh.2011.11-0160","volume":"85","author":"KC Kobylinski","year":"2011","unstructured":"Kobylinski KC, Sylla M, Chapman PL, Sarr MD, Foy BD. Ivermectin mass drug administration to humans disrupts malaria parasite transmission in Senegalese villages. Am J Trop Med Hyg. 2011;85:3\u20135.","journal-title":"Am J Trop Med Hyg"},{"key":"4624_CR24","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1186\/1475-2875-13-417","volume":"13","author":"H Alout","year":"2014","unstructured":"Alout H, Krajacich BJ, Meyers JI, Grubaugh ND, Brackney DE, Kobylinski KC, et al. Evaluation of ivermectin mass drug administration for malaria transmission control across different West African environments. Malar J. 2014;13:417.","journal-title":"Malar J"},{"key":"4624_CR25","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/bcp.13840","volume":"85","author":"U Duthaler","year":"2019","unstructured":"Duthaler U, Suenderhauf C, Karlsson MO, Hussner J, Meyer Zu Schwabedissen H, et al. Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers. Br J Clin Pharmacol. 2019;85:626\u201333.","journal-title":"Br J Clin Pharmacol"},{"key":"4624_CR26","unstructured":"Barcelona Institute for Global Health. A Phase III Cluster-randomized, Open-label, Clinical Trial to Study the Safety and Efficacy of Ivermectin Mass Drug Administration to Reduce Malaria Transmission in Two African Settings. clinicaltrials.gov; 2022. Report No.: NCT04966702. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04966702. Accessed 29 Sep 2022."},{"key":"4624_CR27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1473-3099(21)00557-0","volume":"22","author":"ED Dabira","year":"2022","unstructured":"Dabira ED, Soumare HM, Conteh B, Ceesay F, Ndiath MO, Bradley J, et al. Mass drug administration of ivermectin and dihydroartemisinin\u2013piperaquine against malaria in settings with high coverage of standard control interventions: a cluster-randomised controlled trial in The Gambia. Lancet Infect Dis. 2022;22:519\u201328.","journal-title":"Lancet Infect Dis"},{"key":"4624_CR28","unstructured":"Foy B. Repeat Ivermectin Mass Drug Administrations for Malaria Control II (RIMDAMAL II): a Double-blind, Cluster-randomized Control Trial for Integrated Control of Malaria. clinicaltrials.gov; 2022. Report No.: NCT03967054. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03967054. Accessed 29 Sep 2022."},{"key":"4624_CR29","unstructured":"London School of Hygiene and Tropical Medicine. Adjunctive Ivermectin Mass Drug Administration for Malaria Control on the Bijagos Archipelago of Guinea Bissau: A Cluster-randomized Placebo-controlled Trial [Internet]. clinicaltrials.gov; 2022. Report No.: NCT04844905. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04844905. Accessed 29 Sep 2022."},{"key":"4624_CR30","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12936-015-1063-y","volume":"15","author":"C Chaccour","year":"2016","unstructured":"Chaccour C, Killeen GF. Mind the gap: residual malaria transmission, veterinary endectocides and livestock as targets for malaria vector control. Malar J. 2016;15:24.","journal-title":"Malar J"},{"key":"4624_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2016-000198","volume":"2","author":"GF Killeen","year":"2017","unstructured":"Killeen GF, Kiware SS, Okumu FO, Sinka ME, Moyes CL, Massey NC, et al. Going beyond personal protection against mosquito bites to eliminate malaria transmission: population suppression of malaria vectors that exploit both human and animal blood. BMJ Glob Health. 2017;2: e000198.","journal-title":"BMJ Glob Health"},{"key":"4624_CR32","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13063-023-07098-2","volume":"24","author":"C Chaccour","year":"2023","unstructured":"Chaccour C, Casellas A, Hammann F, Ruiz-Castillo P, Nicolas P, Monta\u00f1a J, et al. BOHEMIA: Broad One Health Endectocide-based Malaria Intervention in Africa\u2014a phase III cluster-randomized, open-label, clinical trial to study the safety and efficacy of ivermectin mass drug administration to reduce malaria transmission in two African settings. Trials. 2023;24:128.","journal-title":"Trials"},{"key":"4624_CR33","doi-asserted-by":"publisher","first-page":"24900","DOI":"10.1073\/pnas.2003976117","volume":"117","author":"ME Sinka","year":"2020","unstructured":"Sinka ME, Pironon S, Massey NC, Longbottom J, Hemingway J, Moyes CL, et al. A new malaria vector in Africa: predicting the expansion range of Anopheles stephensi and identifying the urban populations at risk. Proc Natl Acad Sci USA. 2020;117:24900\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4624_CR34","doi-asserted-by":"crossref","unstructured":"Ochomo E, Milanoi S, Abongo BO, Onyango B. Molecular surveillance leads to the first detection of Anopheles stephensi in Kenya. Research Square. 2023. https:\/\/www.researchsquare.com. Accessed 27 Jan 2023.","DOI":"10.21203\/rs.3.rs-2498485\/v1"},{"key":"4624_CR35","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/BF00316107","volume":"39","author":"U Klotz","year":"1990","unstructured":"Klotz U, Ogbuokiri JE, Okonkwo PO. Ivermectin binds avidly to plasma proteins. Eur J Clin Pharmacol. 1990;39:607\u20138.","journal-title":"Eur J Clin Pharmacol"},{"key":"4624_CR36","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s002280050131","volume":"50","author":"OZ Baraka","year":"1996","unstructured":"Baraka OZ, Mahmoud BM, Marschke CK, Geary TG, Homeida MMA, Williams JF. Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus. Eur J Clin Pharmacol. 1996;50:407\u201310.","journal-title":"Eur J Clin Pharmacol"},{"key":"4624_CR37","first-page":"438","volume":"75","author":"U Duthaler","year":"2020","unstructured":"Duthaler U, Leisegang R, Karlsson MO, Kr\u00e4henb\u00fchl S, Hammann F. The effect of food on the pharmacokinetics of oral ivermectin. J Antimicrob Chemother. 2020;75:438\u201340.","journal-title":"J Antimicrob Chemother"},{"key":"4624_CR38","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1208\/s12248-007-9000-9","volume":"10","author":"A Gonz\u00e1lez Canga","year":"2008","unstructured":"Gonz\u00e1lez Canga A, Sahag\u00fan Prieto AM, Diez Li\u00e9bana MJ, Fern\u00e1ndez Mart\u00ednez N, Sierra Vega M, Garc\u00eda Vieitez JJ. The pharmacokinetics and interactions of ivermectin in humans\u2014a mini-review. AAPS J. 2008;10:42\u20136.","journal-title":"AAPS J"},{"key":"4624_CR39","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S0035-9203(00)90211-6","volume":"94","author":"DH Foley","year":"2000","unstructured":"Foley DH, Bryan JH, Lawrence GW. The potential of ivermectin to control the malaria vector Anopheles farauti. Trans R Soc Trop Med Hyg. 2000;94:625\u20138.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"4624_CR40","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/cpt.1716","volume":"107","author":"KC Kobylinski","year":"2020","unstructured":"Kobylinski KC, Jittamala P, Hanboonkunupakarn B, Pukrittayakamee S, Pantuwatana K, Phasomkusolsil S, et al. Safety, pharmacokinetics, and mosquito-lethal effects of ivermectin in combination with dihydroartemisinin-piperaquine and primaquine in healthy adult Thai subjects. Clin Pharmacol Ther. 2020;107:1221\u201330.","journal-title":"Clin Pharmacol Ther"},{"key":"4624_CR41","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/004982598239597","volume":"28","author":"Z Zeng","year":"1998","unstructured":"Zeng Z, Andrew NW, Arison BH, Luffer-Atlas D, Wang RW. Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes. Xenobiotica. 1998;28:313\u201321.","journal-title":"Xenobiotica"},{"key":"4624_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.712","volume":"9","author":"P Tipthara","year":"2021","unstructured":"Tipthara P, Kobylinski KC, Godejohann M, Hanboonkunupakarn B, Roth A, Adams JH, et al. Identification of the metabolites of ivermectin in humans. Pharmacol Res Perspect. 2021;9: e00712.","journal-title":"Pharmacol Res Perspect"},{"issue":"172","key":"4624_CR43","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jpba.2019.04.007","volume":"5","author":"U Duthaler","year":"2019","unstructured":"Duthaler U, Suenderhauf C, Gaugler S, Vetter B, Kr\u00e4henb\u00fchl S, Hammann F. Development and validation of an LC-MS\/MS method for the analysis of ivermectin in plasma, whole blood, and dried blood spots using a fully automatic extraction system. J Pharm Biomed Anal. 2019;5(172):18\u201325.","journal-title":"J Pharm Biomed Anal"},{"key":"4624_CR44","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1038\/s41598-017-03918-z","volume":"7","author":"HF Owusu","year":"2017","unstructured":"Owusu HF, Chitnis N, M\u00fcller P. Insecticide susceptibility of Anopheles mosquitoes changes in response to variations in the larval environment. Sci Rep. 2017;7:3667.","journal-title":"Sci Rep"},{"key":"4624_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0146021","volume":"10","author":"C Ritz","year":"2015","unstructured":"Ritz C, Baty F, Streibig JC, Gerhard D. Dose-response analysis using R. PLoS ONE. 2015;10: e0146021.","journal-title":"PLoS ONE"},{"key":"4624_CR46","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.pt.2014.07.005","volume":"30","author":"S \u014cmura","year":"2014","unstructured":"\u014cmura S, Crump A. Ivermectin: panacea for resource-poor communities? Trends Parasitol. 2014;30:445\u201355.","journal-title":"Trends Parasitol"},{"key":"4624_CR47","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/clpt.1993.46","volume":"53","author":"PO Okonkwo","year":"1993","unstructured":"Okonkwo PO, Ogbuokiri JE, Ofoegbu E, Klotz U. Protein binding and ivermectin estimations in patients with onchocerciasis. Clin Pharmacol Ther. 1993;53:426\u201330.","journal-title":"Clin Pharmacol Ther"},{"key":"4624_CR48","unstructured":"FDA. Drug Development and Drug Interactions. Table of Substrates, Inhibitors and Inducers. FDA [Internet]. 2022. Available from: https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Accessed 14 Dec 2022."},{"key":"4624_CR49","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/86882","volume":"27","author":"P Kuehl","year":"2001","unstructured":"Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383\u201391.","journal-title":"Nat Genet"},{"key":"4624_CR50","first-page":"464","volume":"12","author":"SH Chiu","year":"1984","unstructured":"Chiu SH, Sestokas E, Taub R, Smith JL, Arison B, Lu AY. The metabolism of avermectin-H2B1a and -H2B1b by pig liver microsomes. Drug Metab Dispos. 1984;12:464\u20139.","journal-title":"Drug Metab Dispos"},{"key":"4624_CR51","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1080\/004982597239967","volume":"27","author":"Z Zeng","year":"1997","unstructured":"Zeng Z, Andrew NW, Halley BA. Identification of cytochrome P4503A as the major enzyme sub-family responsible for the metabolism of 22,23-dihydro-13-O-[(2-methoxyethoxy)methyl]-avermectin B1 aglycone by rat liver microsomes. Xenobiotica. 1997;27:985\u201394.","journal-title":"Xenobiotica"},{"key":"4624_CR52","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1017\/S0031182012001680","volume":"140","author":"I Vok\u0159\u00e1l","year":"2013","unstructured":"Vok\u0159\u00e1l I, Jedli\u010dkov\u00e1 V, Jir\u00e1sko R, Stuchl\u00edkov\u00e1 L, B\u00e1rt\u00edkov\u00e1 H, Sk\u00e1lov\u00e1 L, et al. The metabolic fate of ivermectin in host (Ovis aries) and parasite (Haemonchus contortus). Parasitology. 2013;140:361\u20137.","journal-title":"Parasitology"},{"key":"4624_CR53","first-page":"311","volume":"10","author":"C Hugnet","year":"2007","unstructured":"Hugnet C, Lespine A, Alvinerie M. Multiple oral dosing of ketoconazole increases dog exposure to ivermectin. J Pharm Pharm Sci. 2007;10:311\u20138.","journal-title":"J Pharm Pharm Sci"},{"key":"4624_CR54","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.vetpar.2008.06.017","volume":"157","author":"M Alvinerie","year":"2008","unstructured":"Alvinerie M, Dupuy J, Kiki-Mvouaka S, Sutra JF, Lespine A. Ketoconazole increases the plasma levels of ivermectin in sheep. Vet Parasitol. 2008;157:117\u201322.","journal-title":"Vet Parasitol"},{"key":"4624_CR55","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/j.1365-2885.2009.01129.x","volume":"33","author":"M Ballent","year":"2010","unstructured":"Ballent M, Lifschitz A, Virkel G, Mate L, Lanusse C. Pretreatment with the inducers rifampicin and phenobarbital alters ivermectin gastrointestinal disposition. J Vet Pharmacol Ther. 2010;33:252\u20139.","journal-title":"J Vet Pharmacol Ther"},{"key":"4624_CR56","doi-asserted-by":"publisher","first-page":"8535","DOI":"10.1038\/s41598-017-08906-x","volume":"7","author":"CJ Chaccour","year":"2017","unstructured":"Chaccour CJ, Hammann F, Alustiza M, Castejon S, Tarimo BB, Abizanda G, et al. Cytochrome P450\/ABC transporter inhibition simultaneously enhances ivermectin pharmacokinetics in the mammal host and pharmacodynamics in Anopheles gambiae. Sci Rep. 2017;7:8535.","journal-title":"Sci Rep"},{"key":"4624_CR57","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13071-021-04675-9","volume":"14","author":"P Nicolas","year":"2021","unstructured":"Nicolas P, Kiuru C, Wagah MG, Muturi M, Duthaler U, Hammann F, et al. Potential metabolic resistance mechanisms to ivermectin in Anopheles gambiae: a synergist bioassay study. Parasit Vectors. 2021;14:172.","journal-title":"Parasit Vectors"},{"key":"4624_CR58","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1080\/00498250600944300","volume":"36","author":"S Quaranta","year":"2006","unstructured":"Quaranta S, Chevalier D, Allorge D, Lo-Guidice JM, Migot-Nabias F, Kenani A, et al. Ethnic differences in the distribution of CYP3A5 gene polymorphisms. Xenobiotica. 2006;36:1191\u2013200.","journal-title":"Xenobiotica"},{"key":"4624_CR59","volume-title":"Ivermectin for malaria transmission control, technical consultation meeting report","author":"WHO","year":"2016","unstructured":"WHO. Ivermectin for malaria transmission control, technical consultation meeting report. Geneva: World Health Organization; 2016."}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-023-04624-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-023-04624-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-023-04624-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T03:04:16Z","timestamp":1687575856000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-023-04624-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,24]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4624"],"URL":"https:\/\/doi.org\/10.1186\/s12936-023-04624-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2549867\/v1","asserted-by":"object"}]},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,24]]},"assertion":[{"value":"4 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical considerations. Blood samples were taken from a previously published study [\n                      \n                      ].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"194"}}